BRAF V600E NSCLC is a prevalent subtype known for its resistance to BRAF inhibitors, mainly due to the existence of KRAS mutations leading to continuous activation of the MEK pathway regardless of BRAF (156). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.